199 related articles for article (PubMed ID: 15564137)
1. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
2. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
3. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer.
Cheng WS; Dzojic H; Nilsson B; Tötterman TH; Essand M
Cancer Gene Ther; 2006 Jan; 13(1):13-20. PubMed ID: 16052227
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
5. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
6. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
[TBL] [Abstract][Full Text] [Related]
7. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
9. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
11. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
13. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
14. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
15. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
[TBL] [Abstract][Full Text] [Related]
16. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
Terao S; Shirakawa T; Kubo S; Bishunu A; Lee SJ; Goda K; Tsukuda M; Hamada K; Tagawa M; Takenaka A; Fujisawa M; Gotoh A
Urology; 2007 Nov; 70(5):1009-13. PubMed ID: 17919690
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
18. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
19. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
20. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].
Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
